Guntram Buesche
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guntram Buesche has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Hans Heinrich Kreipe
Institute of Pathology, Hannover Medical School (MHH), Hannover, Germany
3 shared publications Ulrich Germing
Department of Hematology, Oncology and Clinical Immunology Heinrich‐Heine‐University Duesseldorf Germany
2 shared publicationsA. Ganser
Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Duisburg, Germany
1 shared publicationA. Giagounidis
Department of Oncology, Hematology, and Palliative Treatment, Marienhospital, Düsseldorf, Duisburg, Germany
1 shared publicationAristoteles Giagounidis
Department of Oncology, Hematology, and Palliative Treatment Marien‐Hospital Düsseldorf Germany
1 shared publication- Aristoteles Giagounidis
Klinik für Onkologie, Hämatologie und Palliativmedizin, Marien Hospital Düsseldorf, Düsseldorf, Germany
1 shared publication
Latest Publications
- Open Access
- 1 April 2022
- Published by Wiley in British Journal of Haematology
- Vol. 198 (1) , 114-130
Evolution of severe (transfusion‐dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage‐associated failure of the eythropoietic niche
Summary: Evolution of erythrocyte transfusion‐dependent (RBC‐TD) anaemia associated with haploinsufficiency of the ribosomal protein subunit S14 gene (RPS14) is a characteristic complication of myelodysplastic syndromes (MDS) with del(5q) [MDS.del(5q)]. Evaluating 39 patients with MDS.del(5q), RPS14‐dependent alterations of normoblasts, pro‐erythroblasts, or CD34+CD71+ precursors. Ninety‐three percent of anaemia progression and 70% of the absolute decline in peripheral blood Hb value were attributable to disappearance of erythroblastic islands (Ery‐Is). Ery‐Is loss occurred independently of blast excess, TP53 mutation, additional chromosome aberrations and RPS14‐dependent alterations of normoblasts and pro‐erythroblasts. It was associated with RPS14‐dependent intrinsic (S100A8+) and extrinsic [tumour necrosis factor α (TNF‐α)‐overproduction] alterations of (CD169+) marrow macrophages (p < 0.00005). In a mouse model of RPS14 haploinsufficiency, Ery‐Is disappeared to a similar degree: approximately 70% of Ery‐Is loss was related to RPS14‐dependent S100A8 overexpression of marrow macrophages, less than 20% to that of CD71highTer119− immature precursors, and less than 5% to S100A8/p53 overexpression of normoblasts or pro‐erythroblasts. Marked Ery‐Is loss predicted reduced efficacy (erythrocyte transfusion independence) of lenalidomide therapy (p = 0.0006). Thus, erythroid hypoplasia, a characteristic complication of MDS.del(5q), seems to result primarily from a macrophage‐associated failure of the erythropoietic niche markedly reducing the productive capacity of erythropoiesis as the leading factor in anaemia progression and evolution of RBC‐TD in MDS.del(5q).
- 1 April 2022
- Published by Wiley in British Journal of Haematology
- Vol. 198 (1) , 114-130
Open AccessEvolution of severe (transfusion‐dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage‐associated failure of the eythropoietic niche
Summary: Evolution of erythrocyte transfusion‐dependent (RBC‐TD) anaemia associated with haploinsufficiency of the ribosomal protein subunit S14 gene (RPS14) is a characteristic complication of myelodysplastic syndromes (MDS) with del(5q) [MDS.del(5q)]. Evaluating 39 patients with MDS.del(5q), RPS14‐dependent alterations of normoblasts, pro‐erythroblasts, or CD34+CD71+ precursors. Ninety‐three percent of anaemia progression and 70% of the absolute decline in peripheral blood Hb value were attributable to disappearance of erythroblastic islands (Ery‐Is). Ery‐Is loss occurred independently of blast excess, TP53 mutation, additional chromosome aberrations and RPS14‐dependent alterations of normoblasts and pro‐erythroblasts. It was associated with RPS14‐dependent intrinsic (S100A8+) and extrinsic [tumour necrosis factor α (TNF‐α)‐overproduction] alterations of (CD169+) marrow macrophages (p < 0.00005). In a mouse model of RPS14 haploinsufficiency, Ery‐Is disappeared to a similar degree: approximately 70% of Ery‐Is loss was related to RPS14‐dependent S100A8 overexpression of marrow macrophages, less than 20% to that of CD71highTer119− immature precursors, and less than 5% to S100A8/p53 overexpression of normoblasts or pro‐erythroblasts. Marked Ery‐Is loss predicted reduced efficacy (erythrocyte transfusion independence) of lenalidomide therapy (p = 0.0006). Thus, erythroid hypoplasia, a characteristic complication of MDS.del(5q), seems to result primarily from a macrophage‐associated failure of the erythropoietic niche markedly reducing the productive capacity of erythropoiesis as the leading factor in anaemia progression and evolution of RBC‐TD in MDS.del(5q).
- Open Access
- 21 October 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (10) , 3269
Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion
Myelodysplastic syndrome (MDS) can easily transform into acute myeloid leukemia (AML), a process which is often associated with clonal evolution and development of complex karyotypes. Deletion of 5q (del(5q)) is the most frequent aberration in complex karyotypes. This prompted us to analyze clonal evolution in MDS patients with del(5q). There were 1684 patients with low and intermediate-risk MDS and del(5q) with or without one additional cytogenetic abnormality, who were investigated cytogenetically in our department, involving standard karyotyping, fluorescence in situ hybridization (FISH) and multicolor FISH. We identified 134 patients (8%) with aspects of clonal evolution. There are two main routes of cytogenetic clonal evolution: a stepwise accumulation of cytogenetic events over time and a catastrophic event, which we defined as the occurrence of two or more aberrations present at the same time, leading to a sudden development of highly complex clones. Of the 134 patients, 61% underwent a stepwise accumulation of events whereas 39% displayed a catastrophic event. Patients with isolated del(5q) showed significantly more often a stepwise accumulation of events rather than a catastrophic event. The most frequent aberrations in the group of stepwise accumulation were trisomy 8 and trisomy 21 which were significantly more frequent in this group compared to the catastrophic event group. In the group with catastrophic events, del(7q)/-7 and del(17p)/-17 were the most common aberrations. A loss of 17p, containing the tumor suppressor gene TP53, was found significantly more frequent in this group compared to the group of stepwise accumulation. This leads to the assumption that the loss of TP53 is the driving force in patients with del(5q) who undergo a sudden catastrophic event and evolve into complex karyotypes.
- 21 October 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (10) , 3269
Open AccessRoutes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion
Myelodysplastic syndrome (MDS) can easily transform into acute myeloid leukemia (AML), a process which is often associated with clonal evolution and development of complex karyotypes. Deletion of 5q (del(5q)) is the most frequent aberration in complex karyotypes. This prompted us to analyze clonal evolution in MDS patients with del(5q). There were 1684 patients with low and intermediate-risk MDS and del(5q) with or without one additional cytogenetic abnormality, who were investigated cytogenetically in our department, involving standard karyotyping, fluorescence in situ hybridization (FISH) and multicolor FISH. We identified 134 patients (8%) with aspects of clonal evolution. There are two main routes of cytogenetic clonal evolution: a stepwise accumulation of cytogenetic events over time and a catastrophic event, which we defined as the occurrence of two or more aberrations present at the same time, leading to a sudden development of highly complex clones. Of the 134 patients, 61% underwent a stepwise accumulation of events whereas 39% displayed a catastrophic event. Patients with isolated del(5q) showed significantly more often a stepwise accumulation of events rather than a catastrophic event. The most frequent aberrations in the group of stepwise accumulation were trisomy 8 and trisomy 21 which were significantly more frequent in this group compared to the catastrophic event group. In the group with catastrophic events, del(7q)/-7 and del(17p)/-17 were the most common aberrations. A loss of 17p, containing the tumor suppressor gene TP53, was found significantly more frequent in this group compared to the group of stepwise accumulation. This leads to the assumption that the loss of TP53 is the driving force in patients with del(5q) who undergo a sudden catastrophic event and evolve into complex karyotypes.
- Open Access
- 22 September 2017
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 13 (9) , e1006639
The Kaposi's sarcoma-associated herpesvirus (KSHV) non-structural membrane protein K15 is required for viral lytic replication and may represent a therapeutic target
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the infectious cause of the highly vascularized tumor Kaposi’s sarcoma (KS), which is characterized by proliferating spindle cells of endothelial origin, extensive neo-angiogenesis and inflammatory infiltrates. The KSHV K15 protein contributes to the angiogenic and invasive properties of KSHV-infected endothelial cells. Here, we asked whether K15 could also play a role in KSHV lytic replication. Deletion of the K15 gene from the viral genome or its depletion by siRNA lead to reduced virus reactivation, as evidenced by the decreased expression levels of KSHV lytic proteins RTA, K-bZIP, ORF 45 and K8.1 as well as reduced release of infectious virus. Similar results were found for a K1 deletion virus. Deleting either K15 or K1 from the viral genome also compromised the ability of KSHV to activate PLCγ1, Erk1/2 and Akt1. In infected primary lymphatic endothelial (LEC-rKSHV) cells, which have previously been shown to spontaneously display a viral lytic transcription pattern, transfection of siRNA against K15, but not K1, abolished viral lytic replication as well as KSHV-induced spindle cell formation. Using a newly generated monoclonal antibody to K15, we found an abundant K15 protein expression in KS tumor biopsies obtained from HIV positive patients, emphasizing the physiological relevance of our findings. Finally, we used a dominant negative inhibitor of the K15-PLCγ1 interaction to establish proof of principle that pharmacological intervention with K15-dependent pathways may represent a novel approach to block KSHV reactivation and thereby its pathogenesis. Both the latent and lytic replication phases of the KSHV life cycle are thought to contribute to its persistence and pathogenesis. The non-structural signaling membrane protein K15 is involved in the angiogenic and invasive properties of KSHV-infected endothelial cells. Here we show that the K15 protein is required for virus replication, early viral gene expression and virus production through its activation of the cellular signaling pathways PLCγ1 and Erk 1/2. K15 is abundantly expressed in KSHV-infected lymphatic endothelial cells (LECs) and contributes to KSHV-induced endothelial spindle cell formation. The abundant K15 protein expression observed in LECs is also observed in KS tumors. We also show that it may be possible to target K15 in order to intervene therapeutically with KSHV lytic replication and pathogenesis.
- 22 September 2017
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 13 (9) , e1006639
Open AccessThe Kaposi's sarcoma-associated herpesvirus (KSHV) non-structural membrane protein K15 is required for viral lytic replication and may represent a therapeutic target
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the infectious cause of the highly vascularized tumor Kaposi’s sarcoma (KS), which is characterized by proliferating spindle cells of endothelial origin, extensive neo-angiogenesis and inflammatory infiltrates. The KSHV K15 protein contributes to the angiogenic and invasive properties of KSHV-infected endothelial cells. Here, we asked whether K15 could also play a role in KSHV lytic replication. Deletion of the K15 gene from the viral genome or its depletion by siRNA lead to reduced virus reactivation, as evidenced by the decreased expression levels of KSHV lytic proteins RTA, K-bZIP, ORF 45 and K8.1 as well as reduced release of infectious virus. Similar results were found for a K1 deletion virus. Deleting either K15 or K1 from the viral genome also compromised the ability of KSHV to activate PLCγ1, Erk1/2 and Akt1. In infected primary lymphatic endothelial (LEC-rKSHV) cells, which have previously been shown to spontaneously display a viral lytic transcription pattern, transfection of siRNA against K15, but not K1, abolished viral lytic replication as well as KSHV-induced spindle cell formation. Using a newly generated monoclonal antibody to K15, we found an abundant K15 protein expression in KS tumor biopsies obtained from HIV positive patients, emphasizing the physiological relevance of our findings. Finally, we used a dominant negative inhibitor of the K15-PLCγ1 interaction to establish proof of principle that pharmacological intervention with K15-dependent pathways may represent a novel approach to block KSHV reactivation and thereby its pathogenesis. Both the latent and lytic replication phases of the KSHV life cycle are thought to contribute to its persistence and pathogenesis. The non-structural signaling membrane protein K15 is involved in the angiogenic and invasive properties of KSHV-infected endothelial cells. Here we show that the K15 protein is required for virus replication, early viral gene expression and virus production through its activation of the cellular signaling pathways PLCγ1 and Erk 1/2. K15 is abundantly expressed in KSHV-infected lymphatic endothelial cells (LECs) and contributes to KSHV-induced endothelial spindle cell formation. The abundant K15 protein expression observed in LECs is also observed in KS tumors. We also show that it may be possible to target K15 in order to intervene therapeutically with KSHV lytic replication and pathogenesis.
- Open Access
- 4 March 2016
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 101 (5) , e177-e181
Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes
Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E
- 4 March 2016
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 101 (5) , e177-e181
Open AccessImpaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes
Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E
- 19 September 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (11) , 1292-1298
Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide
- 19 September 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (11) , 1292-1298
Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide
- Open Access
- 1 February 2010
- Published by Elsevier in Molecular Therapy
- Vol. 18 (2) , 343-352
Gene Therapy of Mpl Deficiency: Challenging Balance Between Leukemia and Pancytopenia
- 1 February 2010
- Published by Elsevier in Molecular Therapy
- Vol. 18 (2) , 343-352
Open AccessGene Therapy of Mpl Deficiency: Challenging Balance Between Leukemia and Pancytopenia